Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis

Podobne zapisy

• Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases
  od: Quartuccio, Luca, i wsp.
  Wydane: (2020)
• Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
  od: Stone, John H., i wsp.
  Wydane: (2010)
• Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis
  od: Miloslavsky, EM, i wsp.
  Wydane: (2014)
• Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis
  od: McClure, Mark E., i wsp.
  Wydane: (2019)
• PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
  od: van Dam, Laura S, i wsp.
  Wydane: (2020)